Systemic lupus erythmatosus (SLE) is a chronic autoimmune disease characterized by inflammation of various tissues and organs of the body due to the production of autoantibodies.[@b1-asm-3-229] SLE mostly affects the heart, lung, skin, joints, kidney, liver, blood vessels, and nervous system. Diagnosing SLE can be difficult as the symptoms come and go unpredictably. The disease is treatable mostly with corticosteroids and immunosuppressants, but thus far it is incurable and can be fatal. The prevalence of SLE varies among ethnicity and gender. It has been found to occur more frequently among African Americans and those of non-European descent. Also it is more common in women than in men.[@b2-asm-3-229]

The etiology of SLE is unknown; however, several factors that have been considered to trigger as well as exacerbate the disease are hormones,[@b3-asm-3-229] pathogens,[@b4-asm-3-229] medications, and UV light.[@b5-asm-3-229] Moreover, genetic factors have been strongly suggested to contribute to the disease. These were mainly shown by studies on identical twins[@b6-asm-3-229] in addition to observing a higher disease frequency in the relatives of patients with SLE[@b7-asm-3-229] and children of mothers with SLE.[@b8-asm-3-229] Extensive studies have linked SLE susceptibility to genes of the human leukocyte antigen (HLA) region. However, the extent of this association varies among different population.

The aim of this study is to investigate the association between HLA alleles and SLE in our Saudi population.

METHODS
=======

Patients and controls
---------------------

A total of 86 consecutive SLE patients attending the rheumatology clinic at King Abdulaziz Medical City, Riyadh, were recruited for this study. All patients met at least 4 of the 11 American College of Rheumatology criteria.[@b9-asm-3-229] Patients were consented and file review was conducted to collect all clinical and laboratory data. HLA results were compared with 356 ethnically matched controls.[@b10-asm-3-229]

HLA typing
----------

A total of 5 mL peripheral blood was collected in EDTA. DNA was prepared from blood leukocytes using the salting out procedure. White cells were separated using Ficoll Hypaque followed by lysis of erythrocytes in red blood cell lysis buffer and protein digestion in proteinase K solution. Finally, DNA was extracted by precipitating proteins in a saturated salt solution using the QIAamp DNA Blood Mini Kit from Qiagen (Valencia, California). All individuals were DNA typed for HLA-A, HLA-B, HLA-DRB1, and HLA-DQB1 using polymerase chain reaction-sequence specific primer (PCR-SSP) (Deutsche Dynal AG, Hamburg, Germany) using low-resolution typing method.

Statistical analysis
--------------------

The maximum likelihood estimates of allele frequencies and haplotype frequencies were computed using an expectation maximization algorithm by the Arlequin software.[@b11-asm-3-229] To compare the differences between the allele frequencies in the controls and SLE groups, a 2×2 contingency table analysis was performed using the Pearson chi-square tests with Fisher exact test, when the expected value for an HLA marker was \<5. The strength of association between HLA alleles and SLE was estimated by odds ratios (OR) and 95% confidence intervals (95% CI). *P*\<.05 was considered to be statistically significant. For the 2-locus haplotypes, the the standardized disequilibrium coefficient (D′) and the chi-square values were also calculated.

RESULTS
=======

We investigated HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 genes in 86 Saudi SLE patients and compared their results with 356 healthy controls. The female gender dominated showing a ratio of female to male as 10.7:1, with the mean age of 26.1 years at onset and the mean disease duration of 8.8 years ([Table 1](#t1-asm-3-229){ref-type="table"}). Arthritis was the most common clinical presentation, followed by renal involvement, malar rash, leucopenia, and alopecia ([Table 2](#t2-asm-3-229){ref-type="table"}). Most patients presented with ANA (98.9%), anti-DNA (98.9%), and low complement C3 and C4 (93.0%), ([Table 3](#t3-asm-3-229){ref-type="table"}).

[Tables 4](#t4-asm-3-229){ref-type="table"}[](#t5-asm-3-229){ref-type="table"}[](#t6-asm-3-229){ref-type="table"} to [7](#t7-asm-3-229){ref-type="table"} show the HLA class I and class II allele frequencies in both SLE cases and controls. The following HLA types were significantly increased in cases versus controls: HLA-A\*29 (OR 2.70, 95% CI 1.03--7.08, *P*=.035) and HLA-DQB1\*06 (OR 1.67, 95% CI 1.19--2.36, *P*=.032). However, HLA-B\*51 (OR 1.81, 95% CI 1.17--2.79, *P*=.0066) and HLA-DRB1\* 15 (OR 1.49, 95% CI 0.98--2.29, *P*=.063) were marginally significant. HLA-DRB1\*01 (OR 0.16, 95% CI 0.02--1.2, *P*=.041) was protective, whereas HLA-A\*02 (OR 0.69, 95% CI 0.47--1.02, *P*=.06) and HLA-DRB1\*16 (OR 0.18, 95% CI 0.02--1.3, *P*=.055) were marginally protective.

[Table 8](#t8-asm-3-229){ref-type="table"} describes the association between HLA-DRB1\* 15 haplotypes and SLE. Apparently, HLA-DRB1\* 15-DQB1\*06 haplotype carried a significant risk for SLE (OR 2.01, 95% CI 1.20--3.68, *P*=.008) in our Saudi population.

DISCUSSION
==========

We investigated the association of HLA genes in a Saudi cohort of SLE patients. This is the first description of immunogenetics of SLE in Saudi Arabia. The age at onset and the preponderance of females over males in this cohort were similar to other populations.[@b12-asm-3-229]

Two major HLA haplotypes have been shown repeatedly to be associated with SLE worldwide: HLA-DR3 and HLA-DR2 (DR15 and DR16) bearing haplotypes.[@b13-asm-3-229]--[@b16-asm-3-229] Different HLA-DR alleles were reported in different ethnics groups: HLA-DRB1\* 0301 with Caucasians, HLA-DRB1\*1503 with African Americans, and HLA-DRB1\*08 alleles with Hispanics. In our population, HLA-DRB1\*15 haplotypes were found to be associated with SLE in Saudis, while HLA-DRB1\*16 was protective. In Mexicans, DR15 haplotypes were found to be associated with risk for SLE,[@b17-asm-3-229] while, 1 study showed that HLA-DRB1\*16 was associated with chronic discoid lupus in Mexicans.[@b18-asm-3-229] HLA-DRB1\*04 was protective in this Saudi population; the same result was observed in patients from Northwest Spain.[@b19-asm-3-229]

Several studies analyzed the MHC region for genetic risk of SLE. Graham et al[@b20-asm-3-229] narrowed the disease-associated haplotypes HLA-DRB1\*1501-HLA-DQB1\*0602 and HLA-DRB1\*0801-HLA-DQB1\* 0402 to a region of 500 kb. Fernando et al[@b21-asm-3-229] using British SLE families and TdT analysis, narrowed the susceptibility region in MHC to 180 kb that involved the HLA-DRB1\*0301-HLA-DQA1\*0501-HLA-DQB1\* 0201. Our own results suggested that HLA-DRB1\* 15-HLA-DQB1\*06 haplotype is a risk factor for SLE in Saudis; however, looking at the allele frequencies we find that the frequency of HLA-DRB1\*15 is nearly 20% whereas that of HLA-DQB1\*06 is 40%, suggesting that HLA-DQB1\*06 is associated with SLE independent of HLA-DRB1\*15. Thus narrowing the risk area of SLE to the DQB1 region, it still remains elusive whether HLA-DQB1\*06 is the culprit or another gene polymorphism is in linkage disequilibrium with it.

One third of our patients have renal involvement; whereas, in other Asian populations, renal involvement ranged from 18% to 100%, majority reporting \>50% of their patients.[@b22-asm-3-229] In Italians, lupus nephritis was found to be associated with the HLA-DR15-bearing haplotypes; [@b23-asm-3-229] this was also reported in other studies.[@b24-asm-3-229]--[@b26-asm-3-229] In our patients, there was no association between HLA-DR15-bearing haplotypes and lupus nephritis (data not shown). Alarcón et al[@b27-asm-3-229] analyzed factors influencing the development of lupus nephritis. Their results suggested that younger, hypertensive, and of African American or Hispanic ethnicity were predictors of lupus nephritis risk. Moreover, end-stage renal disease was also predicted by the presence of homozygosity for the valine allele of FcγRIIIa (FCGR3A\*GG).[@b27-asm-3-229] This finding suggested that HLA-DR15 is not the only predictor of lupus nephritis risk and thus further analysis is required to determine the risk factors for the development of lupus nephritis in the Saudi patients.

In conclusion, this is the first study to show HLA-DRB1 and HLA-DQB1 associations with SLE in the Saudi population.
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###### 

Demographics of the SLE patients.

  Characteristics              
  ---------------------------- -------------
  Total patient number         86
  F:M                          10.7:1
  Age range of patients        9--60 y
  Mean age at onset (SD)       26.1 10.2 y
  Disease duration mean (SD)   8.8 (5) y

SLE: Systemic lupus erythematosus, F:M: female to male ratio, SD: standard deviation.

###### 

Clinical presentation of SLE patients.

  Clinical presentation   No. (%)
  ----------------------- -----------
  Arthritis               71 (82.6)
  Renal involvement       30 (34.9)
  Alopecia                19 (22.1)
  Raynaud phenomenon      7 (8.1)
  Photosensitivity        11 (12.8)
  Hemolytic anemia        13 (15.1)
  CNS involvement         4 (4.7)
  Malar rash              25 (29.1)
  Oral ulcers             13 (15.1)
  Leukopenia              25 (29.1)
  Thrombocytopenia        9 (10.5)
  Serositis               4 (4.7)
  Pleuritis               4 (4.7)

SLE: Systemic lupus erythematosus, CNS: central nervous system.

###### 

Number and percentage of autoantibody positive SLE patients.

  Autoantibody       No. (%)
  ------------------ -----------
  ANA                85 (98.9)
  Anti-DNA           85 (98.9)
  Low C3 or C4       80 (93.0)
  RNP antibodies     12 (14.0)
  Anti-Sm            5 (5.8)
  Anti-cardiolipin   39 (45.3)
  Anti-Ro            23 (26.7)
  Anti-La            10 (11.6)

SLE: Systemic lupus erythematosus.

###### 

HLA-A associations with SLE in Saudi patients.

  SLE         Controls   OR      95% CI   *P*                         
  ----------- ---------- ------- -------- ------- ------ ------------ ------
  HLA-A\*01   17         0.099   51       0.072                       
  HLA-A\*02   40         0.233   217      0.305   0.69   0.47--1.02   .06
  HLA-A\*03   7          0.041   46       0.065                       
  HLA-A\*11   8          0.047   27       0.038                       
  HLA-A\*23   10         0.058   38       0.053                       
  HLA-A\*24   16         0.093   53       0.074                       
  HLA-A\*25   0          0.000   1        0.001                       
  HLA-A\*26   11         0.058   33       0.046                       
  HLA-A\*29   7          0.041   11       0.015   2.70   1.03--7.08   .035
  HLA-A\*30   7          0.041   39       0.055                       
  HLA-A\*31   16         0.093   50       0.070                       
  HLA-A\*32   4          0.023   37       0.052                       
  HLA-A\*33   7          0.041   43       0.060                       
  HLA-A34     2          0.012   0        0.003                       
  HLA-A66     1          0.006   1        0.001                       
  HLA-A68     15         0.081   55       0.077                       
  HLA-A69     2          0.012   0        0.000                       
  HLA-A74     2          0.012   8        0.011                       

SLE: Systemic lupus erythematosus, OR: odds ratio, HLA: human leukocyte antigen.

###### 

HLA-B associations with SLE in Saudi patients.

  SLE         Controls   OR      95% CI   *P*                         
  ----------- ---------- ------- -------- ------- ------ ------------ -------
  HLA-B\*07   20         0.116   69       0.097                       
  HLA-B\*08   13         0.076   57       0.08                        
  HLA-B\*13   1          0.006   10       0.014                       
  HLA-B\*14   1          0.006   7        0.01                        
  HLA-B\*15   7          0.041   32       0.045                       
  HLA-B\*18   1          0.006   22       0.031                       
  HLA-B\*27   0          0       6        0.008                       
  HLA-B\*35   14         0.081   58       0.081                       
  HLA-B\*37   2          0.012   8        0.011                       
  HLA-B\*38   4          0.023   9        0.013                       
  HLA-B\*39   5          0.029   6        0.008                       
  HLA-B\*40   6          0.035   11       0.015                       
  HLA-B\*41   9          0.052   28       0.039                       
  HLA-B\*42   3          0.017   8        0.011                       
  HLA-B\*44   4          0.023   26       0.037                       
  HLA-B\*45   0          0       2        0.003                       
  HLA-B\*46   0          0       2        0.003                       
  HLA-B\*47   0          0       1        0.001                       
  HLA-B\*49   1          0.006   27       0.038                       
  HLA-B\*50   23         0.134   137      0.192                       
  HLA-B\*51   35         0.203   88       0.124   1.81   1.17--2.79   .0066
  HLA-B\*52   3          0.017   11       0.015                       
  HLA-B\*53   7          0.041   31       0.044                       
  HLA-B\*54   0          0       1        0.001                       
  HLA-B\*55   2          0.012   5        0.007                       
  HLA-B\*56   3          0.017   0        0                           
  HLA-B\*57   2          0.012   15       0.021                       
  HLA-B\*58   6          0.035   27       0.038                       
  HLA-B\*67   0          0       2        0.003                       
  HLA-B\*73   0          0       5        0.007                       
  HLA-B\*78   0          0       1        0.001                       

SLE: Systemic lupus erythematosus, OR: odds ratio, HLA: human leukocyte antigen.

###### 

HLA-DRB1 associations with SLE in Saudi patients.

  SLE            Controls   OR      95% CI   *P*                         
  -------------- ---------- ------- -------- ------- ------ ------------ ------
  HLA-DRB1\*01   1          0.006   25       0.035   0.16   0.02--1.20   .041
  HLA-DRB1\*15   35         0.203   104      0.146   1.49   0.98--2.29   .063
  HLA-DRB1\*16   1          0.006   23       0.032   0.18   0.02--1.30   .055
  HLA-DRB1\*03   30         0.174   103      0.145                       
  HLA-DRB1\*04   17         0.099   114      0.16                        
  HLA-DRB1\*11   12         0.07    49       0.069                       
  HLA-DRB1\*12   0          0       5        0.007                       
  HLA-DRB1\*13   29         0.169   94       0.132                       
  HLA-DRB1\*14   1          0.006   7        0.01                        
  HLA-DRB1\*07   33         0.192   144      0.202                       
  HLA-DRB1\*08   5          0.029   7        0.01                        
  HLA-DRB1\*09   1          0.006   0        0                           
  HLA-DRB1\*10   7          0.041   37       0.052                       

SLE: Systemic lupus erythematosus, OR: odds ratio, HLA: human leukocyte antigen.

###### 

HLA-DQB1 associations with SLE in Saudi patients.

  SLE            Controls   OR      95% CI   *P*                         
  -------------- ---------- ------- -------- ------- ------ ------------ -------
  HLA-DQB1\*02   60         0.349   245      0.344                       
  HLA-DQB1\*03   34         0.198   164      0.23                        
  HLA-DQB1\*04   3          0.017   19       0.027                       
  HLA-DQB1\*05   5          0.029   77       0.108                       
  HLA-DQB1\*06   70         0.407   207      0.291   1.67   1.19--2.36   .0032

SLE: Systemic lupus erythematosus; OR: odds ratio, HLA: human leukocyte antigen.

###### 

Haplotypes in association with SLE.

  SLE                                             Controls                
  ----------------------------------------------- ---------- ------- ---- ------
  HLA-A\*02 HLA-B\*07 HLA-DRB1\*15 HLA-DQB1\*06   8          0.047   27   .038
  HLA-A\*01 HLA-B\*51 HLA-DRB1\*15 HLA-DQB1\*06   4          0.023   0    0
  HLA-A\*02 HLA-B\*51 HLA-DRB1\*15 HLA-DQB1\*06   3          0.017   8    .011
  HLA-A\*31 HLA-B\*35 HLA-DRB1\*15 HLA-DQB1\*06   3          0.017   6    .008
  HLA-A\*02 HLA-B\*50 HLA-DRB1\*15 HLA-DQB1\*06   2          0.012   1    .001

SLE: Systemic lupus erythematosus, human leukocyte antigen.

Note: Having DRB1\*15 haplotypes in SLE compared to controls OR=2.01, 95% (1.20--3.68), *P*=.008.
